AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
LONDON, GREATER LONDON, UNITED KINGDOM, March 28, 2025 /EINPresswire.com/ -- Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
The global market for tenosynovitis drugs has seen impressive growth in recent years, which is only projected to continue. The market size is predicted to surge from $1.19 billion in 2024 to $1.29 billion in 2025, marking an 8.3% compound annual growth rate CAGR. This growth is largely driven by the increasing incidence of sport injuries, rising healthcare expenditure, a growing aging population, amplified awareness about tenosynovitis, and an increased adoption of biologic treatments.
What's Driving this Surge in the Tenosynovitis Drugs Market?
The prevalence of musculoskeletal disorders, a category of injuries affecting muscles, tendons, ligaments, nerves, joints that could hamper movement and cause pain, is on an upward trend. This rise is attributed to aging populations, sedentary lifestyles, and increased occupational hazards. As these disorders become more common, the demand for tenosynovitis drugs, such as anti-inflammatory medications and corticosteroids, is likely to surge. These drugs are crucial in reducing inflammation and relieving pain in musculoskeletal disorders affecting tendons and their sheaths. To provide some context, the Office for Health Improvement and Disparities, a UK-based government department for public health, reported that in 2022, 17.6% of people aged 16 and over claimed to have a long-term musculoskeletal condition, such as arthritis or ongoing back or joint problems, which represented an increase from 17.0% in 2021.
Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=21297&type=smp
What Drives The Oncaspar Market Growth?
Another significant factor fueling the market growth is the rising incidence of sports injuries. From sprains and strains to severe fractures or dislocations, these injuries can seriously disrupt athletic activities or exercise. The reasons behind sports injuries are diverse, including factors like overuse, improper technique, insufficient warm-up or stretching, and collisions with other players or objects. Tenosynovitis drugs play a pivotal role in the treatment of sports injuries, reducing tendon inflammation, alleviating pain, and enabling faster recovery and improved mobility. For instance, in November 2023, Howden Group Holdings Ltd, a UK-based insurance intermediary company, reported a 170% surge in the severity of ankle injuries, a 200% increase in calf/shin injuries, and a 130% rise in hamstring injuries between October 2022 and January 2023, after the FIFA World Cup Qatar 2022.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/tenosynovitis-drugs-global-market-report
Who Are The Key Players And Emerging Trends In The Oncaspar Market?
Companies in the tenosynovitis drugs market, such as Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi S.A., AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila Healthcare, and AdvaCare Pharma, are focusing on the development of advanced drug formulations. This drive towards innovative drug formulations aims to improve efficacy, minimize side effects, and boost patient adherence.
Strategies like delayed-release and controlled-release technologies, that provide prolonged therapeutic effects, reduce dosing frequency, and minimize gastrointestinal irritation, are being implemented. In July 2024, ANI Pharmaceuticals Inc., a US-based pharmaceutical company, announced the FDA approval for its abbreviated new drug application ANDA and launched Naproxen delayed-release tablets, USP, a more affordable alternative to the reference listed drug RLD, EC-Naprosyn, offering extended relief and reduced gastric irritation.
How Is the Tenosynovitis Drugs Market Segmented?
The market for tenosynovitis drugs has the following segments and subsegments:
1 By Drug Type: Nonsteroidal Anti-Inflammatory Drugs NSAIDS, Corticosteroids, Antibiotics, Other Drug Types
2 By Indication: De Quervain Tenosynovitis, Stenosing Tenosynovitis, Trigger Finger, Other Indications
3 By Route Of Administration: Oral, Injectable, Topical
4 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1 By Nonsteroidal Anti-Inflammatory Drugs NSAIDs: Ibuprofen, Naproxen, Diclofenac, Celecoxib
2 By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone, Triamcinolone
3 By Antibiotics: Penicillins, Cephalosporins, Fluoroquinolones, Macrolides
4 By Other Drug Types: Disease-Modifying Anti-Rheumatic Drugs DMARDs, Biologics, Analgesics
What Are the Key Insights from Regional Market Analysis?
In 2024, North America held the dominant market share for tenosynovitis drugs. However, other regions, including Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa, also make substantial contributions to the global market.
Browse For More Similar Reports-
Drugs for Immunotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report
Skin Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report
Pancreatic Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
About The Business Research Company
The Business Research Company provides comprehensive and data-driven reports on over 27 industries, spanning 60+ geographies. Armed with over 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders, we strive to deliver the information you need to stay ahead in your industry game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
